Boston University
Impacts of endogenously expressed, heterozygous Nuclear Factor Kappa B Subunit 1 variants on complicated common variable immune deficiency
Abstract
dc:description.abstractCommon Variable Immune Deficiency (CVID) is among the most clinically significant primary antibody deficiencies (PAD), affecting approximately 1:25,000 individuals. Patients are diagnosed based on impaired B cell development and low antibody titers, both of which increase recurrent infections in these individuals. While these infections are typically managed through intravenous IgG, compared to patients of other PAD, CVID carries a significantly higher risk for developing non-infectious complications such as autoimmunity, lung disease, and gastritis. Current therapies available to these cases rely on immunosuppression, a difficult approach for patients that are already immunocompromised, and therefore these complications have become the leading cause of morbidity and mortality among CVID cohorts. Furthermore, an extreme lack of CVID specific models has prevented studies into the mechanisms of pathology behind complication development that would lead to improved therapies. Despite this, heterozygous variants in the gene Nuclear Factor Kappa B Subunit 1 (NFKB1) have emerged as the most common genetic findings associated with CVID in certain cohorts, but their role in pathology remains unclear. Therefore, the overarching goal of this dissertation is to investigate how heterozygous NKFB1 variants shape the clinical presentation of CVID and to develop a new model for assessing the specific cellular impacts of endogenous NKFB1 variant expression.To achieve this, we first examined a regional cohort of 92 CVID patients, 15 of which had heterozygous NKFB1 variants and 77 of which were genetically undefined. Initially, we measured antibody levels and leukocyte counts from plasma and peripheral blood mononuclear cell samples from each patient. These showed that only monocyte counts trended towards significant elevation in NFKB1 variant patients as compared to their genetically undefined counterparts, but that this did not reach significance after correcting for multiple comparisons. Following this we did find that autoimmune cytopenia, bronchiectasis, and inflammatory bowel disease were all elevated in NFKB1 variant patients along with plasma levels of IL1ra, IL18, TNF, CCL17, CCL22, and CXCL2. Finally, we then compared phenotypes of missense NFKB1 variants to frameshift and nonsense NKFB1 variant patients and observed that frameshift/nonsense variant patients not only had higher disease severity scores, but also significantly higher monocyte counts. These previously unreported findings suggest that NFKB1 variants, and frameshift/nonsense variants most profoundly, may promote complicated CVID and significantly shape the associated monocyte biology. To further investigate the impact of heterozygous NKFB1 frameshift variants on monocytes, we opted to develop an induced pluripotent stem cell (iPSC) based model that would allow us separate the impacts of NFKB1 mutation from the confounding variables of patient genetic background and inflammatory milieu that complicate ex vivo studies of primary samples. We selected a CVID patient that presented with severe gastric inflammation and the heterozygous NKFB1 frameshift variant 1375delT. iPSCs specific to this patient were reprogrammed from PBMCs, and CRISPR-Cas9 editing was used to generate a separate, syngeneic line with the endogenous heterozygous 1375delT corrected. Additionally, a healthy background, WT NKFB1 iPSC line was selected, and CRISPR-Cas9 was used to introduce heterozygous 1375delT into the endogenous NKFB1 expression locus. By differentiating these four lines together into iPSC derived monocyte-like cells (iMONOs), this approach allowed us to study a CVID associated NKFB1 frameshift variant being endogenously expressed in a purified, naïve, disease specific cell type for the first time. iMONOs, with appropriate morphology and CD14/CD45 surface marker expression, could be produced from all four iPSC lines. Based on whole cell protein lysates, it was clear that the endogenous, heterozygous expression of 1375delT was both necessary and sufficient to induce an equivalent haploinsufficiency in p105/p50, the protein products of NFKB1, under both unstimulated and LPS stimulated conditions. By investigating the LPS induced cytokine response of our iMONOs, we also observed that heterozygous 1375delT expression was necessary, but not sufficient to elevate IL-1β release, and that IL-12 and CCL4 release were elevated in iMONOs derived from our CVID patient background. To better understand how NFKB1 haploinsufficiency may relate to cytokine release dysregulation, we performed bulk RNA-seq on unstimulated and LPS stimulated iMONOs from all four of our iPSC lines. This demonstrated that after sample treatment, genetic background was still the principal source of variation in our samples. Together these studies provide the first evidence that monocyte biology is impacted by the expression of a specific CVID associated NFKB1 frameshift mutation. Moreover, our isogenic studies empowered by our unique iPSC model and CRISPR-mediated gene editing demonstrated that genetic background also plays a significant role in the behavior of these variants on CVID pathology. This underscores the need for further patient-specific and fully genetically controlled studies in order to develop a basis for improved therapies for complicated CVID.
Degree
thesis:*- Name thesis:degree_name
- Doctor of Philosophy
- Level thesis:degree_level
- doctoral
- Discipline thesis:degree_discipline
- Molecular and Translational Medicine
- Grantor
- Boston University
- Year dc:date.issued
- 2025
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Hayes, Kevin Michael
- Advisor dc:contributor.advisor
-
- Maglione, Paul
Subjects
dc:subject × 1Rights
- Language dc:language.iso
- en_US
Identifiers
dc:identifier.*- Handle dc:identifier.uri
- https://hdl.handle.net/2144/52132